Literature DB >> 12078861

Radiotherapeutic management of intracranial ependymoma.

Arnold C Paulino1.   

Abstract

Ependymomas comprise about 10% of all pediatric brain tumors. The most consistent prognostic factor for cure has been the extent of surgical resection. Radiation therapy is considered the standard adjuvant treatment, although there has been no randomized trial comparing surgery alone to surgery and postoperative radiotherapy. Craniospinal irradiation has been used in the past to treat these tumors; however, current data indicate that the most common pattern of failure is an isolated local relapse. Furthermore, prophylactic spinal irradiation has not been shown to prevent spinal dissemination. For this reason, most radiation oncologists currently employ localized radiotherapy fields. Available data indicate that doses greater than 45-50 Gy are needed and associated with better local control. Preliminary data using hyperfractionated radiotherapy doses of greater than 65 Gy indicate an improvement in progression-free survival for subtotally respected ependymoma. Chemotherapy can be used to delay institution of radiotherapy in children less than 3 years of age. The role of hemotherapy in older children needs to be further defined.

Entities:  

Mesh:

Year:  2002        PMID: 12078861     DOI: 10.1080/08880010290057318

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  7 in total

1.  Predicting which children are at risk for ependymoma relapse.

Authors:  Kristina Sowar; Jennifer Straessle; Andrew M Donson; Michael Handler; Nicholas K Foreman
Journal:  J Neurooncol       Date:  2006-03-31       Impact factor: 4.130

2.  Dissemination limits the survival of patients with anaplastic ependymoma after extensive surgical resection, meticulous follow up, and intensive treatment for recurrence.

Authors:  Ryuta Saito; Toshihiro Kumabe; Masayuki Kanamori; Yukihiko Sonoda; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2010-02-26       Impact factor: 3.042

3.  A prognostic gene expression signature in infratentorial ependymoma.

Authors:  Khalida Wani; Terri S Armstrong; Elizabeth Vera-Bolanos; Aditya Raghunathan; David Ellison; Richard Gilbertson; Brian Vaillant; Stewart Goldman; Roger J Packer; Maryam Fouladi; Ian Pollack; Tom Mikkelsen; Michael Prados; Antonio Omuro; Riccardo Soffietti; Alicia Ledoux; Charmaine Wilson; Lihong Long; Mark R Gilbert; Ken Aldape
Journal:  Acta Neuropathol       Date:  2012-02-10       Impact factor: 17.088

4.  Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas.

Authors:  Tang-Her Jaing; Huei-Shyong Wang; Pei-Kwei Tsay; Chen-Kan Tseng; Shih-Ming Jung; Kuang-Lin Lin; Tai-Ngar Lui
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

5.  The history of ependymoma management.

Authors:  Kyu-Won Shim; Dong-Seok Kim; Joong-Uhn Choi
Journal:  Childs Nerv Syst       Date:  2009-05-21       Impact factor: 1.475

Review 6.  Ependymal tumors.

Authors:  Timothy J Moynihan
Journal:  Curr Treat Options Oncol       Date:  2003-12

7.  Ependymomas: Prognostic Factors and Outcome Analysis in a Retrospective Series of 33 Patients.

Authors:  Yong-Hyun Chai; Shin Jung; Jung-Kil Lee; In-Young Kim; Woo-Youl Jang; Kyung-Sub Moon; Jae-Hyoo Kim; Kyung-Hwa Lee; Seul-Kee Kim; Tae-Young Jung
Journal:  Brain Tumor Res Treat       Date:  2017-10-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.